SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (277)12/4/2001 2:29:24 PM
From: scaram(o)uche  Read Replies (1) of 1022
 
>> Any scientists out there who can tell us how significant this is ? <<

My gut tells me that I can't, that I must be missing something. Seems superfluous to me, and this is a lot of work for incremental gain or less. There must be something that I'm missing re. light chain and diversity.

But, IMO, Abgenix IP continues to gain over that of MEDX. Consider, for example, the possibility that the XenoMouse has been oversold in general, that relevant B cells are obtained at a low frequency and that class switch variants are even harder to find. In that case, single cell enrichment procedures would confer a significant advantage.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News